Ads
related to: daily routine with hemophilia 1 and 2- Education Specialists
Find a disease education
specialist near you.
- Family Planning Info
Bleeding disorders and pregnancy.
Steps to take before pregnancy.
- Patient Resources
Find helpful resources and videos
for rare bleeding disorders.
- Bleeding Emergencies
Learn how you can prepare for
bleeding emergencies.
- Education Specialists
Search results
Results from the WOW.Com Content Network
Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding. [1] [4]
Physicians specialized in hematology are known as hematologists or haematologists. [2] Their routine work mainly includes the care and treatment of patients with hematological diseases, although some may also work at the hematology laboratory viewing blood films and bone marrow slides under the microscope, interpreting various hematological test results and blood clotting test results.
Haemophilia A affects about 1 in 5,000–10,000, while haemophilia B affects about 1 in 40,000 males at birth. [2] [5] As haemophilia A and B are both X-linked recessive disorders, females are rarely severely affected. [8] Some females with a nonfunctional gene on one of the X chromosomes may be mildly symptomatic. [8]
Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII.These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.
The National Bleeding Disorders Foundation was founded in 1948, as the first national hemophilia advocacy organization in the United States. [2] One of its early initiatives was to secure funding for Comprehensive Hemophilia Diagnostic and Treatment Centers (HTC).
Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia A and hemophilia B. [5] [8] It is an anti-tissue factor pathway inhibitor. [5] [8] The most common adverse reactions include injection site reactions and hives (urticaria). [11]
In the safety and efficacy trial for prevention and treatment of bleeds, in hemophilia patients the success rate for treatment of bleeds was 84.5% (excluding bleeds for which there was no outcome reported) and out of a total of nine surgeries in nine patients performed during the trial, haemostasis was successful in all the surgeries and no ...
Hemophilia A: Protein structure of coagulation factor VIII, of which its deficiency is the cause of haemophilia A. Specialty: Haematology: Symptoms: Prolonged bleeding from common injuries [1] Causes: Factor VIII deficiency [2] Diagnostic method: Bleeding time, [2] coagulation screen, genetic testing: Prevention: Hepatitis B vaccine should be ...
Ads
related to: daily routine with hemophilia 1 and 2